Agios Drug Boosts Hemoglobin in Small Rare Blood Disease Trial

Agios Pharmaceuticals Inc. said its experimental drug for a rare blood disorder boosted production of a critical protein in a mid-stage trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.